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Background: By using the hepatitis C virus (HCV) genotype 2a JFH-1 or its chimeric strains, a HCV infection system
has been previously developed through several methods– such as in vitro-transcribed JFH1-RNA transfection or
stable transfection of the JFH1 cDNA into human hepatoma Huh-7 cell line or its derivatives. However, other
reliable methods for delivery of the HCV genome into cells are still worth trying. The helper-dependent adenovirus
(HDAd) is devoid of all viral coding sequences and has a package capacity of 37 kb, which is suitably large for the
delivery of the HCV genome. Here we report a new method for delivery of the HCV genome into Huh-7 and
HepG2 cells by using the HDAd vector.
Results: Our results demonstrated that the infection of Huh-7 cells with the HDAdJFH1 virus led to efficient HCV
replication and virion production. We found that the HCV viral RNA levels could reach 107 copies per milliliter (ml)
in the culture medium. HDAdJFH1-infected Huh-7 cells could be cultured for 8 passages with the culture medium
remaining infectious for naïve Huh-7 cells throughout this period. This infection system proved effective for
evaluating the anti-HCV effects of IFN-α in Huh-7 cells. Co-infection of HepG2 cells with the HDAdJFH1 and
HDAdmiR-122 virus also resulted in HCV expression and replication.
Conclusion: This is the first report of an HDAd-based strategy for HCV replication and production in vitro.
Keywords: Hepatitis C virus, Cell-culture model, Helper-dependent adenovirusBackground
Hepatitis C virus (HCV) is a 9.6 kb positive-strand RNA
virus and a member of the flavivirus family [1]. It is esti-
mated that approximately 170 million people worldwide
are persistently infected by HCV, which can result in
hepatic fibrosis, cirrhosis and hepatocellular carcinoma
[2]. Current interferon-α based therapy, in combination
with ribavirin, has limited efficacy in only approximately
50% of patients and has severe side effects [3]. HCV rep-
lication takes place in the cytoplasm, and the 9.6 kb
RNA genome encodes a polyprotein localized to the
rough endoplasmic reticulum (ER), where it is cleaved
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reproduction in any medium, provided the ornonstructural (NS2, NS3, NS4A, NS4B, NS5A, and
NS5B) proteins that play important roles in virus repli-
cation, assembly and pathogenesis [4].
HCV research has been hampered by the lack of ad-
equate in vitro and in vivo model systems. Replicons
have been utilized for studying HCV RNA replication,
but these are not useful for studying aspects of virion
production and infection [5]. In 2005, researchers dis-
covered a genotype 2a isolate JFH1 from a Japanese
patient with fulminant hepatitis that could exhibit
complete the virus life cycle after transfection of in vitro
transcribed full-length JFH1 RNA into Huh-7 or Huh-
7.5 cells. This system is also able to produce infectious
viral particles in cell culture (HCVcc) [6,7]. Furthermore,
it was found that stable human hepatoma cell lines
containing a chromosomally integrated cDNA copy oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the 3′ end can constitutively produce infectious viral
particles [8]. These methods have proven to be effective
in generating infectious HCV cell culture models in
Huh-7 cell line and its derivatives.
In contrast to Huh-7 cells, the hepatocellular carcin-
oma derived HepG2 cells polarize and would thus per-
mit the investigation of how cell polarization impacts
the HCV life cycle [9]. However, HepG2 cells does not
express endogenous miR-122, a liver-expressed miRNA
which is required to support HCV RNA replication [10],
and weakly supports HCV replication [11]. Although a
recent study has indicated that HepG2 cells expressing
miR-122 can support the entire HCV life cycle [11], the
efficiency of HCV replication and virion production still
needs increasing. Thus other potential methods be-
sides transfection for delivery of the HCV genome into
cells are still worth trying especially when the cells,
such as HepG2 cells, possess a relatively lower trans-
fection efficiency.
Adenoviruses (Ads) are non-enveloped double-stranded
DNA viruses, which can mediate efficient transduction
and expression of foreign genes in cells [12]. The helper-
dependent adenovirus (HDAd) possesses the same ability
to deliver foreign DNA into cells as earlier generation ade-
noviruses (Ads); furthermore, HDAd vectors are devoid of
all viral coding sequences and have cloning capacities of
up to 37 kb [13], which makes it possible to introduce
large genes into cells using HDAd vectors. Lacking all
viral coding sequences, it displays only minimal immuno-
genicity and negligible side-effects and allows for long-
term transgene expression in animal models for delivery
of transgenes into the liver, skeletal muscle, myocardium
or brain [14]. Furthermore, it does not integrate into the
host genome, which makes them a promising class of po-
tential delivery vehicles for human gene therapy [15].
In this study, we developed a HDAd vector containing
the full-length JFH1 genome and an HDV ribozyme se-
quence located at the 3′ end of the JFH1 genome. Our
results demonstrate that the HDAd vector was able to
efficiently deliver the HCV genome into Huh-7 cells and
HepG2 cells, in which infectious HCV particles could be
produced in vitro. To our knowledge, an efficient
HDAd-based method for introducing the full-length
9.6 kb HCV RNA genome into hepatocytes has not been
previously described. Therefore, this is the first report of
an in vitro HDAd-mediated HCV genomic replication
and production system.
Results
Construction of a helper-dependent adenoviral vector
expressing the HCV RNA genome
An Ad5 vector has been previously used for the intro-
duction of the hepatitis B viral genome into culturedcells and mice, and it was found that high-titer hepatitis
B virions were secreted into the culture medium of
infected hepatoma cells and the sera of infected mice
[16]. However, the size of the transgene that can be de-
livered by the conventional Ad5 vector is limited to 8.1-
8.2 kb [17], which is nearly the size of the HCV replicon.
Although an Ad5/35 chimera vector was recently used
to generate a HCV subgenomic-replicon construct [18],
there have been no reports of the packaging and transfer
of the full 9.6 kb HCV genome in vitro or in vivo. In this
study, we aimed to develop a simple and reliable method
for packaging and delivering the HCV genome into cells
to establish a novel HCV infection system. To this end,
we chose to utilize the genotype 2a JFH1 HCV clone
due to its efficient replication in human hepatoma [19]
and mouse cells [20]. The full-length JFH1 RNA genome
is under the control of a 5′ minimal CMV promoter in
the HDAd vector, and the 3′ terminus of the transcript
is processed by an HDV ribozyme sequence. The helper-
dependent adenovirus plasmid also contained a GFP ex-
pression cassette (Figure 1a).
Amplification of the HDAdHCV virus and infection of cells
As quantified by absorbance, the titer of the amplified
and purified HDAdJFH1, HDAdJFH1/GND, HDAdmiR-
122 and HDAdGFP virus were found to be 2×1011,
3×1011, 1×1011, 2×1011viral particles/ml, respectively.
Huh-7 cells and HepG2 cells were infected by the
HDAds at a ratio of 200 viral particles/cell. GFP expres-
sion was observed in the infected Huh-7 and HepG2
cells at 3 days p.i. (Figure 1b). At 3 days p.i, nearly all
the Huh-7 and HepG2 cells were infected with the
HDAdJFH1 virus and had high levels of GFP expression.
Detection of HDAd-mediated HCV protein expression and
RNA replication
HDAd can mediate the efficient delivery and strong ex-
pression of foreign DNA sequences in vitro [21]. Our re-
sults indicate that HDAd can also mediate the efficient
expression of HCV proteins in HDAdJFH1-infected
Huh-7 cells. The expression of HCV core and NS3 pro-
teins was confirmed by immunofluorescence staining
and western blotting using core- and NS3-specific
monoclonal antibodies. At 3 days p.i., immunofluores-
cence staining for HCV core and NS3 were both positive
(Figure 2a). High levels of HCV core and NS3 proteins
were also detected by western blotting at 36 h and 72 h
p.i., respectively (Figure 2b). The expression of HCV
NS3 protein was still detectable at 20 days p.i. (data not
shown), demonstrating the long-term expression of the
HCV genome.
Actinomycin-D has been shown to have the ability to
inhibit transcription [22]. Thus, actinomycin-D was
added in the cell culture medium and northern blot was
Figure 1 Infection of Huh-7 cells and HepG2 cells by the HDAdJFH1 virus. (a). A diagram depicting the genetic makeup of HDAdJFH1. The
transcriptional expression of the JFH1 RNA genome is under the control of the CMV promoter and the HDV ribozyme. The GFP expression
cassette is under the control of a second CMV promoter and contains an SV40 polyA tail. (b). GFP expression in HDAdJFH1-infected Huh-7 cells
and HepG2 cells on day 3 p.i. Magnification, ×10 (b).
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concentration of actinomycin-D was maintained 5 μg/ml
in the medium for 16 hours in HDAdJFH1, HDAdJFH1/
GND-infected Huh-7cells and HDAdJFH1-infected 293
cells since 6 hours p.i. After actinomycin-D treatment,
expression of intracellular HCV RNA can be detected in
the HDAdJFH1-infected Huh-7 cells, compared with
those in the HDAdJFH1/GND-infected Huh-7 cells and
HDAdJFH1-infected 293 cells (Figure 2c). The resultsFigure 2 HCV expression and replication in HDAdJFH1-infected Huh-7
proteins in Huh-7 cells on day 3 p.i. HDAdGFP-infected Huh-7 cells served
NS3 proteins in HDAdJFH1-infected Huh-7 cells at 36 h and 72 h p.i. Huh-7
positive control. HDAdGFP-infected Huh-7 cells served as a negative contro
infected Huh-7 cells, HDAdJFH1/GND-infected Huh-7 cells and the HDAdJF
infected cells without actinomycin-D served as controls. Magnification, ×40indicated that actinomycin-D inhibited the HDAd-
mediated HCV genome transcription in HDAdJFH1/
GND-infected Huh-7 cells and HCV replicated in the
HDAdJFH1-infected Huh-7 cells. Quantitative RT-PCR
analysis also showed an increase of HCV RNA levels in
the cell culture medium since HDAdJFH1 infection of
Huh-7 cells (Figure 3). Together, these results demon-
strated the replication of HCV genome in the HDAd-
JFH1-infected Huh-7 cells.cells. (a). Immunofluorescence assays (IFAs) of the HCV core and NS3
as a negative control. (b). Western blots detecting the HCV core and
cells transfected with in vitro-transcribed JFH1 RNA served as a
l. (c). Northern blots detecting HCV RNA and 28S rRNA in HDAdJFH1-
H1-infected 293 cells in the presence of actinomycin-D. A group of
(a).
Figure 3 Quantification of the HCV RNA levels in the cells and supernatants. HCV RNA levels were analyzed by RT-qPCR with the
HDAdJFH1/GND-infected Huh-7 cells and the HDAdJFH1-infected 293 cells as controls. The supernatant infectivity titers were determined in naïve
Huh-7 cells and were expressed as ffu/ml (indicated with bars).
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Huh-7 cell culture medium
We found that HCV RNA levels in the cell culture
medium of the HDAdJFH1-infected Huh-7 cells first in-
creased to a maximal level at 16 days p.i. and then de-
creased in the following days. While HCV RNA levels in
the supernatant of the HDAdJFH1/GND-infected Huh-7
cells decreased gradually (Figure 3). Based on these find-
ings, we wondered whether HDAd-mediated HCV vi-
rions were present in the cell culture medium. ToFigure 4 Infectious HCV production in Huh-7 cells following HDAdJFH
with supernatant from HDAdJFH1-infected Huh-7 cells that were collected
GND-infected Huh-7 cells collected on day 17 p.i. served as negative contro
antibody. The infectious HCV supernatants were pre-incubated with the ind
h at 37°C before addition to naïve Huh-7 cells. Huh-7 cells were pre-incuba
mouse IgG antibodies for 1 h at 37°C before addition of the infectious HCVHDAdJFH1-infected Huh-7 cells, we infected naïve
Huh-7 cells with the medium for 1 h at 37°C; we subse-
quently determined the expression levels of the HCV
NS3 protein using IFA. As shown in Figure 4a, naïve
Huh-7 cells were infected with medium collected at day
17 p.i., cultured for another 3 days and then assayed for
HCV NS3 protein expression using IFA. Naïve Huh-7
cells served as a negative control. Huh-7 cells were also
infected with medium from HDAdJFH1/GND-infected
Huh-7 cells to confirm that HDAdJFH1 infection1 infection. (a). IFA of the HCV NS3 protein in Huh-7 cells infected
on day 17 p.i. Huh-7 cells infected with supernatant from HDAdJFH1/
ls. (b). Inhibition of HCV infection by the anti-E2 and anti-CD81
icated concentrations of anti-E2 or control mouse IgG antibodies for 1
ted with the indicated concentrations of anti-human CD81 or control
supernatant. Total cellular RNA was analyzed by RT-qPCR on day 3 p.i.
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into the medium of HDAdJFH1-infected Huh-7 cells.
To determine in more detail the infectious titer of
HCV, the medium was serially diluted in 10-fold incre-
ments and used to infect Huh-7 cells. The infectious
titer was determined by counting the number of cell foci
that stained positive for HCV NS3 protein at the lowest
dilution point, which was then multiplied by the dilution
factor (n-fold) [6]. The infectious HCV titer of the
medium reached a maximal level of 1×103 ffu/ml at 16
days p.i. (Figure 3) and was comparable to the infectious
HCV titer in Huh-7 cell by conventional transfection of
in vitro transcribed JFH1 RNA, which normally only
reaches 102~103 ffu/ml.
HCV infection is inhibited by anti-E2 and anti-CD81
antibodies
Previous studies using pseudotyped viruses expressing
HCV E1/E2 have suggested that the interaction between
E2 and CD81 is crucial for viral entry [23,24]. To further
investigate the infectivity of the HCV virions, we
performed infectivity-neutralization and inhibition ex-
periments using monoclonal antibodies specific for HCV
E2 and CD81. Prior to addition to the Huh-7 cells, the
infectious HCV supernatant was pre-incubated with a
dilution series of a mouse monoclonal antibody specific
for HCV E2. An irrelevant human IgG1 antibody served
as a negative control. In another experiment, the Huh-7
cells were pre-incubated with CD81 antibodies before
the infectious HCV supernatant was added. The irrele-
vant mouse IgG1 antibody served as a negative control.
For both the E2 and CD81 antibody treatments, the
intracellular HCV RNA levels were observed to decrease
in a dose-dependent manner by 3 days p.i. A concentra-
tion of 5 μg/ml of anti-E2 antibody was sufficient to
cause a 50% reduction in the intracellular HCV RNA
level by 3 days p.i., whereas only 0.5 μg/ml of anti-CD81
antibody was sufficient to cause the same reductionFigure 5 HCV infectivity determination by density gradient analysis a
produced HCV particles. Concentrated culture medium collected from HDA
infectivity titers in each fraction was determined. (b). Infection of naïve Huh
and infection kinetics assay analysis.(Figure 4b). These results are consistent with the previ-
ously reported findings [6,7] and confirm the infectivity
of the cell culture medium.
To characterize the produced HCV virions, the culture
medium of the HDAdJFH1-infected Huh-7 cells was
subjected to sucrose density gradient centrifugation. The
fractions were analyzed for HCV RNA levels, as well as
the infectivity titers. As shown in Figure 5a, a peak for
HCV RNA level and infectivity titer was found in frac-
tion 4, which has a density of 1.15 g/ml. This density is
almost consistent with the published density of HCV vi-
rions [8,25]. The infection kinetics assay showed that the
cellular HCV RNA levels increased to 107 copies within
7 days p.i. (Figure 5b). These results further confirm the
production of infectious HCV virions in this HDAd-
mediated system.
Inhibition of HCV replication by IFN-α
Previous studies have shown that IFN-α can successfully
inhibit HCV replication both in Huh-7 cells transfected
with JFH1 RNA [6] and in Huh-7 cells with a stably inte-
grated HCV genome [8]. Therefore, we investigated the
inhibitory effects of IFN-α on HCV replication in our
HDAd-mediated infection system. Beginning at 8 days
p.i., HDAdJFH1-infected Huh-7 cells were incubated
with DMEM containing different concentrations of IFN-
α for 3 days, and levels of the NS3 protein were deter-
mined by western blotting. IFN-α efficiently inhibited
HCV replication in HDAdJFH1-infected Huh-7 cells
(Figure 6). Therefore, it is likely that this HDAd-
mediated HCV infection system is suitable for the evalu-
ation of new anti-HCV drugs and therapeutic strategies.
HDAdJFH1 and HDAdmiR-122 virus co-infection mediate
HCV expression and replication in HepG2 cells
HepG2 cells does not express endogenous miR-122, a
liver-expressed miRNA which is required to support
HCV RNA replication [10], and weakly supports HCVnd infection kinetics assay. (a). Density gradient analysis of
dJFH1-infected Huh-7 cells was fractionated, HCV RNA levels and HCV
-7 cell by the supernatant from the HDAd-JFH1-infected Huh-7 cells
Figure 6 IFN-α inhibition of HCV replication in HDAdJFH1-
infected Huh-7 cells. The effects of IFN-α on HCV replication were
determined by western blot analysis of HCV NS3 expression.
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HepG2 cells expressing miR-122 can support the entire
HCV life cycle [11]. In this study, we tested whether the
HDAd system can work in HepG2 cells. Results showed
that co-infection of HepG2 cells with HDAdJFH1 and
HDAdmiR-122 virus enhances HCV core and NS3Figure 7 HCV expression and replication in HepG2 cells co-infected w
and NS3 proteins in HepG2 cells co-infected with HDAdJFH1 and HDAdmi
HDAdJFH1–infected HepG2 cells served as controls. (b). Quantification of th
HepG2 cells and supernatants. Magnification, ×40 (a).protein expression (Figure 7a). Kinetic analysis of HCV
RNA levels in the co-infected HepG2 cells and culture
medium were performed. Compared with the HDAdJFH1/
GND infection control, HDAdJFH1 and HDAdmiR-122
co-infection resulted in relatively weak replication of HCV
genome, as shown in Figure 7b.
Discussion
Hepatitis C virus (HCV) is a positive-strand RNA virus
that was first identified in 1989. Since then, both basic
and pharmaceutical research on HCV has been ham-
pered by a lack of viral culturing systems [4]. Early stud-
ies on HCV mainly focused on the structure and
function of the individual viral genes, and later studies
utilized HCV subgenomic replicons, which were more
effective for HCV RNA replication research and antiviral
development [20,26]. However, the replicon system is
not suitable for HCV life-cycle research due to this sys-
tem’s inability to produce infectious HCV virions. In
2005, it was reported that RNA generated from the JFH1
viral genome can produce infectious HCV virions when
transfected into Huh-7 cells [7]. Both transient and
stable transfections with DNA vectors expressing theith HDAdJFH1 and HDAdmiR122 virus. (a). IFAs of the HCV core
R122 virus on day 3 p.i. HDAdGFP-infected HepG2 cells and
e HCV RNA levels in the HDAdJFH1 and HDAdJFH1/GND-infected
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[8,25] and in these studies it was found that the HDV
ribozyme plays an important role in cleavage of the
HCV RNA product.
It appears that efficient delivery of the HCV RNA gen-
ome, for example by electroporation or stable transfec-
tion, is vital for the efficient replication and production
of the HCV virus. Here, we report on the use of the
helper-dependent adenoviral (HDAd) vector, which can
mediate high-efficiency transduction of one or more for-
eign genes into cells [27]. Adenoviruses (Ads) are non-
enveloped double-stranded DNA viruses, replication and
assembly of which take place in the nucleus. Adenovirus
vectors are most effective at mediating the transfer of
foreign DNA into immortalized and primary cells. In the
liver, they predominantly infect hepatocytes [21], where
hepatitis-virus replication and infection take place.
Adenoviral vectors have been used for the transfer of the
genome of the hepatitis B virus into cultured cells and
mice [16]. However, the 9.6 kb HCV RNA genome was
too large to be introduced into early generation Ad vec-
tors. HDAds are constructed by removing all viral se-
quences from earlier generation Ad vectors except for
the packaging sequences and the inverted terminal re-
peats, which eliminates viral gene expression, liver tox-
icity, and the cellular immune responses elicited by Ad
vectors [28]. As most of the viral coding sequences are
deleted, HDAds have a large delivery capacity of up to
37 kb [29]. As a comparison, the upper size limit of
transgenes that can be delivered with the conventional
Ad5 vector is 8.1-8.2 kb [17] – approximately the size of
the HCV replicon. Thus, it has been difficult to package
the HCV replicon into Ad5, although an Ad5/35
chimera vector has recently been used to generate an
HCV subgenomic-replicon construct [11]. To our know-
ledge, a convenient and efficient method for transferring
the 9.6 kb HCV RNA genome into cells by HDAds has
not been previously reported.
In this study, we developed an HDAd vector
containing the full-length JFH1 genome and an HDV
ribozyme sequence. HDAdJFH1 virus with a high infec-
tious titer was prepared and used to infect Huh-7 cells
in vitro, and we observed both long-term expression and
replication of HCV genome (Figures 2 and 3). HCV rep-
lication was confirmed by de novo RNA synthesis in the
presence of actinomycin-D. The HCV RNA levels in the
supernatants increased to a maximal level of about 107
copies/ml at 16 days p.i. when many cells became
rounded and floated in the culture medium, a similar cy-
topathic effect that can be observed on the JFH1-
transfected Huh-7 cells [30]. Ten days after infection,
the supernatant from HDAdJFH1-infected Huh-7 cells
was found to be infectious and the infectivity of HCV
could be inhibited by anti-E2 and anti-CD81 antibodiesin a dose-dependent manner (Figure 4b). As the inter-
action between E2 and CD81 is vital for HCV entry
[31,32], we believed that HCV particles were being se-
creted into the supernatant of HDAdJFH1-infected
Huh-7 cells. Sucrose density gradient analysis showed
that the virus produced owns a density which is similar
to published data for HCV virions [25]. Furthermore,
we found that IFN-α efficiently inhibited HCV replica-
tion (Figure 6), further validating the potential of this
system for the evaluation of HCV antiviral drugs. Taken
together, our findings demonstrate long-term replica-
tion of the HCV genome and production of infectious
HCV virions in this helper-dependent adenovirus-
mediated system in Huh-7 cells.
MicroRNAs (miRNA) are 21~22 nucleotide RNA mol-
ecules that are expressed in a wide range of eukaryotic
organisms that are predicted to downregulate the ex-
pression of the endogenous target genes by reducing
mRNA stability or translation [33]. MiR-122 is liver-
specific and required for efficient HCV RNA replication
[10,34]. HepG2 cells does not express endogenous miR-
122 and weakly supports HCV replication [11]. A recent
study has indicated that HepG2 cells expressing miR-122
can support the entire HCV life cycle [11]. In this study,
our results also showed that HDAd-mediated miR-122 ex-
pression was necessary for the HDAd-mediated efficient
HCV expression and replication (Figure 7).
Although the method based on in vitro-transcribed
JFH1-RNA transfection is very well established so far, it
is less efficient for primary hepatocytes which are diffi-
cult to transfect. Helper-dependent adenovirus can infect
a variety of different cell types, including hepatic cell
lines, primary hepatocytes [35], as well as quiescent,
non-dividing, or terminally differentiated somatic cells
[36], with high expression efficiency. Thus, by using this
HDAd system, HCV replication or infection can be stud-
ied in the above cell types in vitro. So far, HCV can only
infect human and chimpanzees in vivo and the host
range for HCV infection is narrow. Although human
liver chimeric mice can be infected by HCV, it is immu-
nodeficient with a high mortality rate and the source of
human primary hepatocytes is limited. And it is import-
ant to generate a novel immunocompetent mouse model
which can support HCV replication and infection. Al-
though expression of the four humanized HCV recep-
tors in mice enhance its susceptibility to HCV infection
[37,38], it is still not successful for mediating HCV infec-
tion in mice. Several studies have shown that HDAds
are able to mediate high-level and long-term transgene
expression in animal models, especially for the liver-
targeted gene therapy [13,14]. So it is probable that
HDAd can mediate efficient delivery of the HCV gen-
ome into the mouse livers, but whether HDAd can
mediate HCV genomic replication or even virion
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since extrahepatic manifestations caused by hepatitis C
virus infection exists clinically [39], animal model for
studying HCV extrahepatic manifectations still lacks.
And this HDAd-mediated HCV genomic replication
system provides a possible strategy for generating an
HCV extrahepatic replication model in vivo.Conclusion
This is the first report of an in vitro HDAd-mediated
HCV genomic replication and production system, which
would allow a broader examination of interactions be-
tween HCV and host cell biology, as well as provide
tools for anti-HCV drug evaluation.Methods
Helper-dependent adenoviral vector construction
The plasmid pJFH1 contains the full-length JFH1 cDNA
downstream of the T7 RNA promoter [7]. To replace
the T7 promoter from pJFH1 with CMV promoter, a
PCR fragment, amplified 5′ partial sequence of the HCV
genome in pJFH1 using the chimeric forward primer 5′-
ccgaattcgagctcggtacccgg-3′ which consists of two seg-
ments lying beside the upstream and downstream of T7
promoter and reverse primer 5′-caccggttccgcagaccac-3′,
was inserted into pJFH1 between the restriction enzyme
sites for EcoR I and Age I that locates upstream and
downstream of the T7 promoter respectively. The
resulting construct was designated pJFH1(ΔT7). A hepa-
titis delta virus (HDV) ribozyme DNA sequence was
synthesized and placed at the immediate 3′ end of
pJFH1(ΔT7), to get pJFH1-ribo(ΔT7). The JFH1-ribo se-
quence was then inserted between the CMV promoter
and SV40PolyA of the pSC11 plasmid by the restriction
enzyme sites for EcoR I and Hind III. And this expres-
sion cassette was finally inserted into the HDAd vector
between the restriction enzyme sites for I-Ceu I and I-
Sce I. The resulting construct, HDAdJFH1, also contains
a cassette for the expression of green fluorescent protein
(GFP) [40]. HDAdJFH1/GND was constructed with the
same strategy. And an empty HDAd plasmid expressing
GFP (HDAdGFP) served as a control.
Using the Huh-7 cells derived total RNA-reverse tran-
scribed cDNA as a template, the human genomic miR-122
precursor sequence was amplified by RT-PCR using the for-
ward and reverse primers 5′-ccggaattcttcgtggctacagagttt-3′
and 5′-cccaagctttttatcgagggaaggatt-3′, and then inserted
into the pSC11 plasmid by the restriction enzyme sites for
EcoR I and Hind III. And this expression cassette was finally
inserted into the HDAd vector between the restriction en-
zyme sites for I-Ceu I and I-Sce I. The resulting construct
was designated HDAdmiR-122.Cells and cell culture methods used in this study
A modified version of the 293 cell line that expresses high
levels of the Cre enzyme – known as the 116 cell line
(kindly provided by Dr. Li-min Liu) – was maintained in
MEM supplemented with 10% fetal bovine serum (FBS),
0.1 mg/ml hygromycin, 100 U/ml penicillin, 100 μg/ml
streptomycin, and 2 mM L-glutamine (Invitrogen) [41].
The hepatoma cell lines Huh-7, HepG2, as well as non-
hepatic 293 cell line, were obtained from ATCC (Manassas,
VA) and maintained in DMEM supplemented with
100 U/ml penicillin, 100 μg/ml streptomycin, nones-
sential amino acids, and 10% FBS (Invitrogen).Amplification of the HDAdHCV virus and infection of cells
The helper-dependent adenoviral plasmids, including
HDAdJFH1, HDAdJFH1/GND, HDAdmiR-122, HDAdGFP,
were digested with the restriction enzyme PmeI to release
both inverted terminal repeats and were then transfected
into 116 cells with the calcium phosphate method, respect-
ively [42]. Helper-dependent adenoviral particles were pre-
pared by repeated amplification cycles in 116 cells with the
helper virus AdNG163 (a kind gift of Dr. Li-min Liu; see
above). After 4-6 rounds of amplification in 150-mm
dishes, 116 cells suspended in a 3 L spinner flask were
infected for large-scale preparation of HDAdJFH1,
HDAdJFH1/GND, HDAdmiR-122, HDAdGFP. The viral
particles were isolated by centrifugation in a cesium chlor-
ide gradient, followed by dialysis with three exchanges of 10
mM Tris-HCl (pH 8.0) at 4°C [43]. Virus particles were
quantified by measuring the absorbance at 260 nm [44].
Huh-7, HepG2 and 293 cells were infected with the purified
HDAds at 80% confluency with an MOI of 200 viral parti-
cles/cell and were passaged every 2 or 3 days.Western blot analysis
The HDAdJFH1-infected Huh-7 cells were lysed in pro-
tein sample buffer containing 50 mM Tris-HCl, 150 mM
NaCl, 5 mM EDTA, 0.2 mM sodium orthovanadate, 1%
Triton X-100, 1% sodium deoxycholate, and 1% sodium
dodecyl sulfate; the buffer was also supplemented with
aprotinin (2 μg/ml), pepstatin A (0.7 μg/ml), leupeptin
(0.5 μg/ml), and PMSF (1 mM). For each sample, 30 μg
of total protein was electrophoresed through a 10% so-
dium dodecyl sulfate-polyacrylamide gel and transferred
onto a nitrocellulose membrane. The membrane was
blocked by pre-incubation with 5% skim milk. The levels
of the HCV core and NS3 proteins were determined using
monoclonal antibodies specific to the core and NS3 pro-
teins (Thermo Scientific), which were detected with a
horseradish peroxidase-conjugated goat anti-mouse im-
munoglobulin G antibody (IgG, Pierce) and visualized
with a chemiluminescent substrate (Pierce). The level of
the GAPDH protein served as an internal control, and this
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antibody (Sigma).
Immunofluorescence assays (IFAs)
The HDAdJFH1-infected Huh-7 and HepG2 cells were
grown overnight on coverslips in a 6-well culture plate.
Cells were washed with 1× phosphate-buffered saline
(PBS), fixed with chilled acetone, and blocked with 1% bo-
vine serum albumin and 1% goat serum in PBS. The local-
izations of the HCV core and NS3 proteins were
visualized in the fixed cells by incubation with core- and
NS3-specific monoclonal antibodies and a secondary goat
anti-mouse IgG antibody conjugated to DyLight™594
fluorescein (used at a 1:800 dilution) (Beijing Golden
Bridge Biotechnology, Beijing, China). The HDAdGFP-
infected Huh-7 and HepG2 cells served as a negative con-
trol. The coverslips were then mounted onto slides, and
the HCV proteins were visualized with a Zeiss Axioplan 2
fluorescence microscope.
Quantification of HCV RNA levels
Total cellular RNA was extracted from infected cells
using the RNeasy RNA isolation kit (Qiagen). Total
RNA was extracted from the supernatants of the
infected cells using the QIAamp Viral RNA Mini Kit
(Qiagen). The RNA concentration was determined by
spectrophotometry. RT-qPCR was performed as de-
scribed elsewhere [6], and the HCV levels were deter-
mined relative to a standard curve created using serial
dilutions of a plasmid containing the HCV JFH1 cDNA.
Northern blot analysis of intracellular viral RNA levels
To confirm the replication of HCV genome, actinomycin-
D (Sigma) was maintained in the cell culture medium
at a concentration of 5 μg/ml for 16h in HDAdJFH1,
HDAdJFH1/GND-infected Huh-7cells and HDAdJFH1-
infected 293 cells since 6 hours p.i.. Total cellular RNA
was extracted from infected Huh-7 cells using the
RNeasy RNA isolation kit (Qiagen). Four micrograms
of isolated RNA was separated using a 1% agarose gel
containing formaldehyde, blotted onto a positively charged
nylon membrane (Hybond-N+, GE), and immobilized
with a Stratalinker UV crosslinker (Stratagene). The DNA
probes complementary to a region of the HCV 5′UTR and
human 28S rRNA was synthesized using the DIG High
Prime DNA Labeling and Detection Starter Kit II (Roche).
HCV infection and infectivity neutralization
Naïve Huh-7 cells in a 6-well culture plate were infected
with 1 ml of cultured supernatant from HDAdJFH1-
infected Huh-7 cells. At 3 h postinfection (p.i.), the super-
natants were replaced with 2 ml of DMEM containing
10% FBS, and the cells were incubated at 37°C for 3 days
prior to the protein and RNA analysis. At 3 days p.i., theHCV infectivity was determined by IFA for the HCV core
and NS3 proteins using core- and NS3-specific monoclo-
nal antibodies, respectively. Titration of infectious HCV
was performed by focus forming assay. Cell supernatants
were serially diluted 10-fold in complete DMEM and used
to infect naïve Huh-7 cells. The level of infectious HCV
titer was determined by the average number of NS3-
positive foci detected at highest dilutions at 3 days p.i.. For
the infectivity-neutralization experiments, monoclonal
antibodies specific to HCV E2 and CD81 (Santa Cruz Bio-
technology) were diluted with the HCV-containing culture
medium at 3 days p.i.; normal mouse IgG1 (Santa Cruz
Biotechnology) antibodies were used as negative controls.
The effects of the E2 and CD81 monoclonal antibodies on
HCV infectivity and replication were determined by RT-
qPCR.
Sucrose density gradient analysis
We collected the cell culture medium of the HDAdJFH1-
infected Huh-7 cells at 16 days p.i. using low-speed centrifu-
gation and passed it through a 0.45-μm filter. Then the fil-
trate was layered on a sucrose gradient (60%~10%, wt/vol)
and centrifuged it for 16 h. The fractions were harvested
and analyzed for the HCV RNA levels and infectivity titers.
IFN-α inhibition of HCV replication in HDAdJFH1-infected
Huh-7 cells
For the IFN-α inhibition experiments, Huh-7 cells were
infected with HDAdJFH1 and incubated with DMEM
containing increasing concentrations of IFN-α (Sigma) for 3
days. The effects of IFN-α on HCV replication were deter-
mined using western blot analysis of HCV NS3 expression.
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